| Name | Title | Contact Details |
|---|---|---|
Patrick Johnson |
Vice President of Information Technology and Digital Systems | Profile |
Founded in 2013 and based in the San Francisco Bay Area, Zymergen integrates automation, machine learning, and genomics to rapidly accelerate the pace of scientific advancement. We treat the genome as a search space, leveraging machine learning to make discoveries far beyond the bounds of human intuition. In doing so, we deliver economic value, material diversity and performance capabilities not previously possible.
Bayer and CRISPR Therapeutics have entered into an agreement to create Casebia to discover, develop and commercialize new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart disease. CRISPR Therapeutics will contribute its proprietary CRISPR-Cas9 gene-editing technology and intellectual property, while Bayer will make available its protein engineering expertise and relevant disease know-how. It is the first long-term strategic partnership of its kind to make a substantial investment in the development of target delivery systems in an effort to bring systemic in vivo CRISPR-Cas9 gene editing technology applications to patients.
Flagship Pioneering is an American life sciences venture capital company based in Cambridge, Massachusetts that invests in biotechnology, life sciences, health and sustainability companies.
We Develop first in class therapies for basal cell carcinomas, including those in gorlin syndrome.
AmacaThera is a Toronto-based biotechnology company focused on developing and commercializing a unique, injectable hydrogel platform technology for a wide range of medical applications.